The two-part, multi-center U.S. study will enroll up to 68 patients with non-resectable, recurrent or metastatic breast cancer who have visible lesions or lesions accessible by injection. The study is designed to assess the safety and efficacy of the drug combination of Ad-RTS IL-12 and palifosfamide. Ad-RTS IL-12 is a targeted and controlled DNA-based therapeutic designed to express interleukin-12 (IL-12), a protein important for an immune response to cancer. Palifosfamide is a potent bi-functional DNA alkylating agent.
Find out if this is the moment investors been waiting for before trading ZIOP here:
OCZ Technology Group, Inc. (NASDAQ: OCZ) announced that it has entered into a $30 million loan and security agreement with Hercules Technology Growth Capital, Inc. This loan agreement consists of a $15 million term loan and a $15 million revolving loan facility.
OCZ Technology Group, Inc. engages in the design, manufacture, and distribution of solid state drives (SSDs) and computer components.
Find out where OCZ could be headed by getting the full trend analysis report here:
Disclosure: WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.
Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.